

Anexo 2.**Tabla de referencias de la búsqueda en las bases de datos**

<p>1. Chen J, Wang J, Ni T, He H, Zheng Q. Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma. <i>Medicine (Baltimore)</i>. 2020 Jun 19;99(25):e19908. doi: 10.1097/MD.00000000000019908. PMID: 32569154, PMCID: PMC7310739</p>
<p>2. Zheng B, Wang X, Wei M, Wang Q, Li J, Bi L, Deng X, Wang Z. First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis. <i>BMC Cancer</i>. 2019 Mar 28;19(1):280. doi: 10.1186/s12885-019-5481-z. PMID: 30922269, PMCID: PMC6437996</p>
<p>3. da Silva WC, de Araujo VE, Lima EMEA, Dos Santos JBR, Silva MRRD, Almeida PHRF, de Assis Acurcio F, Godman B, Kurdi A, Cherchiglia ML, Andrade EIG. Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>BioDrugs</i>. 2018 Dec;32(6):585-606. doi:10.1007/s40259-018-0322-1. PMID: 30499082, PMCID: PMC6290722</p>
<p>4. Modest DP, Denecke T, Pratschke J, Ricard I, Lang H, Bemelmans M, Becker T, Rentsch M, Seehofer D, Bruns CJ, Gebauer B, Modest HI, Held S, Folprecht G, Heinemann V, Neumann UP. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. <i>Eur J Cancer</i>. 2018 Jan;88:77-86. doi: 10.1016/j.ejca.2017.10.028. Epub 2017 Nov 28. PMID: 29195117</p>
<p>5. Modest DP, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Westphalen CB, Holch JW, von Einem JC, Held S,</p>

Heinemann V; for FIRE-3/AIOKRK0306-investigators. Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). *Eur J Cancer*. 2017 Oct; 84:262-269. doi: 10.1016/j.ejca.2017.07.030. Epub 2017 Aug 23.] PMID: 28843184

6. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. *JAMA*. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105.] PMID: 28632865, PMCID: PMC5545896

7. Stintzing S, Miller-Phillips L, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 Investigators.. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. *Eur J Cancer*. 2017 Jul;79:50-60. doi: 10.1016/j.ejca.2017.03.023. Epub 2017 Apr 29. PMID: 28463756

8. Modest DP, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Kirchner T, Jung A, Stauch M, von Einem JC, Moehler M, Held S, Heinemann V; FIRE-3 study investigators.. Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306). *Int J Cancer*. 2017 Apr 15;140(8):1918-1925. doi: 10.1002/ijc.30592. Epub 2017 Feb 8. PMID: 28032641

9. Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of

first-line clinical trials. *Eur J Cancer*. 2017 Jan;70:87-98. doi:

10.1016/j.ejca.2016.10.007. Epub 2016 Nov 29. PMID: 27907852

10. Chen K, Gong Y, Zhang Q, Shen Y, Zhou T. Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis. *Medicine (Baltimore)*. 2016

Nov;95(46):e5221. PMID: 27861344, PMCID: PMC5120901

11. Ba-Sang DZ, Long ZW, Teng H, Zhao XP, Qiu J, Li MS. A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer. *Oncotarget*. 2016 Dec 20;7(51):84468-84479. doi: 10.18632/oncotarget.12994.] PMID: 27806321, PMCID: PMC5356673

12. Price T, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Guan X, Peeters M. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPCCCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. *Eur J Cancer*. 2016 Nov;68:51-59. doi:

10.1016/j.ejca.2016.08.010. Epub 2016 Oct 5. PMID: 27716478

13. Heinemann V, Rivera F, O'Neil BH, Stintzing S, Koukakis R, Terwey JH, Douillard JY. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. *Eur J Cancer*. 2016

Nov;67:11-20. doi: 10.1016/j.ejca.2016.07.019. Epub 2016 Sep 1. PMID: 27592068

14. Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen-Jung C, Moehler M, Jagenburg A, Kirchner T, Jung A, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. *Lancet Oncol*. 2016 Oct;17(10):1426-1434. doi:

10.1016/S1470-2045(16)30269-8. Epub 2016 Aug 27. Erratum in: *Lancet Oncol*. 2016

Oct;17 (10):e420. Erratum in: Lancet Oncol. 2016 Nov;17 (11):e479. PMID: 27575024

15. Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Möhler M, Jung A, Kirchner T, Heinemann V. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. *J Clin Oncol*. 2015 Nov 10;33(32):3718-26. doi: 10.1200/JCO.2015.61.2887. Epub 2015 Aug 10. PMID: 26261259

16. Hatano E, Okuno M, Nakamura K, Ishii T, Seo S, Taura K, Yasuchika K, Yazawa T, Zaima M, Kanazawa A, Terajima H, Kaihara S, Adachi Y, Inoue N, Furumoto K, Manaka D, Tokka A, Furuyama H, Doi K, Hirose T, Horimatsu T, Hasegawa S, et al. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study). *J Hepatobiliary Pancreat Sci*. 2015 Aug;22(8):634-45. doi: 10.1002/jhbp.254. Epub 2015 Apr 29. PMID: 25926024

17. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31. PMID: 25088940

18. Qi WX, Shen Z, Tang LN, Yao Y. Does the addition of targeted biological agents to first-line chemotherapy for advanced colorectal cancer increase complete response? A systematic review and meta-analysis. *Colorectal Dis*. 2014 Sep;16(9):O300-7. doi: 10.1111/codi.12647. Review. PMID: 24766530

19. Stintzing S, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Jäger E,

Heintges T, Stoll C, Giessen C, Modest DP, Neumann J, Jung A, Kirchner T, Scheithauer W, Heinemann V. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. *Ann Oncol.* 2012 Jul;23(7):1693-9. doi: 10.1093/annonc/mdr571. Epub 2012 Jan 4. PMID: 22219013

20. Vale CL, Tierney JF, Fisher D, Adams RA, Kaplan R, Maughan TS, Parmar MK, Meade AM. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. *Cancer Treat Rev.* 2012 Oct;38(6):618-25. doi: 10.1016/j.ctrv.2011.11.002. Epub 2011 Nov 26. Review. PMID: 22118887

21. Saltz L, Badarinath S, Dakhil S, Bienvenu B, Harker WG, Birchfield G, Tokaz LK, Barrera D, Conkling PR, O'Rourke MA, Richards DA, Reidy D, Solit D, Vakiani E, Capanu M, Scales A, Zhan F, Boehm KA, Asmar L, Cohn A. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. *Clin Colorectal Cancer.* 2012 Jun;11(2):101-11. doi: 10.1016/j.clcc.2011.05.006. Epub 2011 Nov 4. PMID: 22055112

22. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *N Engl J Med.* 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268. Erratum in: *N Engl J Med.* 2010Dec 23;363(26):2573. PMID: 19196673

23. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Mol L, Antonini NF, Punt CJ. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. *Ann Oncol.* 2008 Apr;19(4):734-8. doi: 10.1093/annonc/mdm607. Epub 2008 Feb 13. PMID: 18272912

24. CALGB/SWOG C80405: A phase III trial of FOLFIRI or FOLFOX with bevacizumab or cetuximab or both for untreated metastatic adenocarcinoma of the colon or rectum. Clin Adv Hematol Oncol. 2006 Jun;4(6):452-3. PMID: 16981668